ESOXC-ER Efficacy and Safety of an Extended Release (ER) Formulation of Oxcarbazepine (Apydan Extent) in Epileptic Patients
N/A
The aim of the observational study is to investigate the safety of oxcarbaz...
Status
Completed
Location
Dr. Stephan Arnold
Start Date
2010-02
Trial ID
NCT01086501
The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Bipolar Disorder I or II This Study is Not Being Conducted in the United States.
PHASE4
Bipolar disorder is a psychiatric illness with clinical characteristics of ...
The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Adolescents With Impulsivity and Aggressive Behavior in Conduct Disorder This Study is Not Being Conducted in the United States.
PHASE4
Conduct disorder is a group of psychiatric symptoms that can include clinic...